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A gateway to more productive research on e-cigarettes?
Commentary on a comprehensive framework for
evaluating public health impact
The widespread use of the comprehensive framework
proposed by Levy and colleagues for evaluating the overall
public health impact of e-cigarettes would advance the ﬁeld.
Time–series analysis of frequent cross-sectional population
data on smoking and quitting activities could be invaluable
in estimating key parameters for such models.
E-cigarettes are controversial among tobacco control and
public health experts [1–3]. Part of the reason is that oppo-
nents and proponents focus upon different parts of the
complicated equation that will determine their overall im-
pact on public health, and there have been few attempts
to quantify and integrate all the determinants into an
overarching population model [4,5]. Levy and colleagues
describe a novel and ambitious framework for evaluating
the public health impact of e-cigarettes [6]. A particular
attraction is that their framework appears comprehensive
and necessarily complex. The authors draw upon systems
thinking and decision theory to cover all possible transi-
tions among never, current and former smokers to a vari-
ety of ﬁnal states of nicotine use. In each case, they argue
that the overall impact will depend upon how e-cigarette
use inﬂuences the long-term prevalence of each ﬁnal state
compared with the counterfactual situation in which
e-cigarettes do not exist.
This type of framework helpfully draws attention to the
possibility of certain scenarios in which e-cigarettes reduce
overall harm, despite the assumption of many opponents
that they will increase harm: for example, e-cigarettes
could actually reduce harm to never smokers who would
have otherwise initiated long-term cigarette use. It would
be a huge advance if this paper moved the ﬁeld towards
consensus on the key parameters necessary to produce
judgements on the overall population impact of
e-cigarettes. Adoption of a common framework and lan-
guage would make the ﬁeld more productive, even if re-
searchers continued to disagree on how to interpret
different studies when parameterizing andweighting differ-
ent parts of the model. The positive impact of a ‘Russell
Standard’ for evaluating clinical interventions is testament
to the importance of common language in the ﬁeld [7].
Levy and colleagues employ the novel framework to
structure a balanced and progressive review of literature
that could be used to parameterise the model [6]. Greater
beneﬁt will arise when using the model to simulate ap-
praisals of overall impact under a variety of different esti-
mates and assumptions. In terms of literature and
methods for parameterizing themodel, the paper cites trials
and cross-sectional surveys, and notes that interpretation
of the latter can be enhanced by matching methods, which
have been used to address a variety of thorny issues in
tobacco control [8–10]. Finally, their conclusion empha-
sizes the importance of large-scale longitudinal studies,
such as the US Population Assessment of Tobacco and
Health (PATH) survey and the International Tobacco
Control (ITC) surveys. The ITC will be particularly impor-
tant beyond its contribution of longitudinal data by also
providing a means of evaluating natural experiments
arising from different countries adopting different regula-
tory approaches [11,12].
An additional type of data—not explicitly mentioned in
their commentary—is likely to prove valuable in this
context; namely, frequent cross-sectional time–series popu-
lation data on important smoking and quitting activities.
Time–series analysis of these population trends would pro-
vide direct estimates of both population level associations
between variables over time and the associated impact of
new policies and regulations, while adjusting for important
confounders and seasonal and long-term trends [13]. Asso-
ciations cannot establish a causal association unequivocally
but they can be indicative as, for example, in estimates of
the relationships between price and cigarette consumption
[14], mass media expenditure and the use of freely available
behavioural support [15], changes to national incentives
for general practitioners to offer evidence-based advice
and referral behaviour [16] and the introduction of
varenicline and use of other cessation medication [17]. In
a more relevant recent example, we have argued that the
growth in the use of e-cigarettes by English smokers was
probably not responsible for the decline in the use of
licensed nicotine products [18]. In this example, our time–
series evidence could be a factor in estimating the counter-
factual pathway of current smokers in Levy and colleagues’
framework because the number of smokers who would
have quit in the absence of e-cigarettes is not due only to
their relative efﬁcacy in cessation, but also whether and
how their availability effects other quitting activity.
Importantly, Levy and colleagues acknowledge that
critical information for populating the framework will need
to be updated continually, and likely only directly applicable
to contexts from which that information is derived. Many
of the estimated transitions are liable to depend upon a va-
riety of cultural and contextual factors, including the pre-
vailing tobacco control environments.
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Tobacco harm reduction from clean nicotine delivery is
at least 40years old [19]. The idea is beautifully simple, but
this paper by Levy and colleagues underscores the
complexity in evaluating the impact of related products.
While the current focus is on e-cigarettes, other novel
devices—such as heat-not-burn tobacco products—loom
that will complicate the modelling [20]. In order to mini-
mize the growing number of global avoidable deaths from
tobacco, scientists should rely upon clear and common
frameworks with explicit parameterization when
considering the range of possible public health effects.
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